Pear Therapeutics, Inc. Warrant
PEARW
PEARW was delisted on the 18th of April, 2023.
36 hedge funds and large institutions have $5.76M invested in Pear Therapeutics, Inc. Warrant in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
57% more capital invested
Capital invested by funds: $3.67M → $5.76M (+$2.09M)
0% more funds holding
Funds holding: 36 → 36 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
+$110K |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$73.3K |
| 3 |
QGA
Q Global Advisors
Fort Worth,
Texas
|
+$36.6K |
| 4 |
PI
PEAK6 Investments
Chicago,
Illinois
|
+$9.77K |
| 5 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$2.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MA
MYDA Advisors
Woodmere,
New York
|
-$9K |
| 2 |
HF
HRT Financial
New York
|
-$2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1K |
| 4 |
AR
Advisory Research
Chicago,
Illinois
|
-$830 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$748 |
PEARW Hedge Fund Activity: Q3 2022 in Review
36 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Warrant (PEARW) for Q3 2022, worth a combined $5.76M — up 57% from $3.67M a quarter earlier.
Fund positioning in PEARW was balanced in Q3 2022: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Walleye Capital, adding an estimated $110K. The largest seller was MYDA Advisors, exiting entirely with an estimated $9K sold.
- 36 institutional investors held Pear Therapeutics, Inc. Warrant (PEARW) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $5.76M of Pear Therapeutics, Inc. Warrant stock for Q3 2022, up 57% quarter-over-quarter.
- 4 funds opened new Pear Therapeutics, Inc. Warrant positions in Q3 2022 and 4 closed out, a net change of 0 holders.
- The largest Pear Therapeutics, Inc. Warrant buyer in Q3 2022 was Walleye Capital, an estimated $110K added.
- The largest Pear Therapeutics, Inc. Warrant seller in Q3 2022 was MYDA Advisors, an estimated $9K sold.
Based on aggregated 13F filings for Q3 2022.